As­traZeneca touts Imfinzi im­munother­a­py com­bos for lung can­cer in push to dri­ve PD-L1 drug up­take

Fac­ing the big dogs in the PD-(L)1 space, As­traZeneca has tak­en its own con­tender Imfinzi in­to block­buster ter­ri­to­ry in its four years on the mar­ket but sees even big­ger things for the drug. Com­bi­na­tions could be the key, and ear­ly re­sults from a mid-stage test are adding some fu­el to that strat­e­gy.

Imfinzi com­bined with one of two in­ves­ti­ga­tion­al im­munother­a­pies — a CD73 an­ti­body dubbed ole­clum­ab or an In­nate’s an­ti-NGK2a named mon­al­izum­ab — topped Imfinzi alone in terms of over­all re­sponse and pro­gres­sion-free sur­vival in pa­tients with stage III non-small cell lung can­cer whose tu­mors had not wors­ened dur­ing con­cur­rent chemora­di­a­tion, ac­cord­ing to in­ter­im da­ta from the Phase II COAST tri­al set to be pre­sent­ed at #ES­MO21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER